HAE stock forecast, quote, news & analysis
Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces... Show more
Haemonetics Corporation (HAE) Stock Analysis: Transformation Complete as Plasma and Hospital Recovery Drive Momentum
Key Takeaways
- Haemonetics shares have risen approximately 3.4% over the past 30 days and more than 19% over the last quarter, reflecting growing investor confidence following the completion of the company's multi-year transformation plan.
- Fiscal Q4 2026 results beat consensus estimates, with revenue of $346 million and adjusted EPS of $1.29, driven by record performances in Plasma and Blood Management Technologies.
- BofA Securities upgraded HAE from Neutral to Buy in late May, while Mizuho raised its price target to $90, and Citi lifted its target to $79 despite a Neutral rating.
- FDA clearance of Persona PLUS and the pending FDA review of PerQseal Elite represent key innovation catalysts that could accelerate growth in fiscal 2027 and beyond.
- Fiscal 2027 guidance calls for 4% to 7% reported revenue growth and continued adjusted operating margin expansion of 50 to 100 basis points.
Current Market Snapshot
Haemonetics Corporation (HAE) has traded with positive momentum in recent weeks, supported by improving fundamentals and favorable analyst sentiment. As of late July 2026, the stock has gained roughly 3.4% over the trailing 30-day period and more than 19% over the last quarter, reflecting a steady recovery from earlier-year levels. The company, which carries a market capitalization of approximately $3.6 billion, has seen its shares benefit from the completion of a four-year transformation plan that has reshaped its portfolio toward higher-margin, recurring-revenue platforms. The broader medical technology sector has provided a supportive backdrop, though Haemonetics' recent performance also reflects company-specific catalysts including strong Plasma segment execution, hospital business recovery, and an active innovation pipeline.
Haemonetics Corporation (HAE) Business Overview and Competitive Position
Haemonetics Corporation, headquartered in Boston, Massachusetts, is a global medical technology company specializing in blood management solutions across the healthcare continuum. Founded in 1971, the company operates through two recently restructured reportable segments: Apheresis (combining the former Plasma and Blood Center segments) and MedSurg (formerly Hospital). Its core platforms include the NexSys PCS plasma collection system with Persona technology, which holds over 50% market share in U.S. plasma collections; the TEG 6s hemostasis analyzer, which commands approximately 45% global share in viscoelastic testing; and the VASCADE family of vascular closure devices. Haemonetics generates roughly 75% of revenue in the United States and benefits from a highly recurring revenue model, with consumables and disposables accounting for the majority of sales. The company serves plasma collection centers, hospitals, and blood centers worldwide, positioning it as a critical supplier in the growing global plasma-derived therapeutics market.
Recent Developments Driving HAE
Several verified catalysts have shaped Haemonetics' recent trajectory. The company reported fiscal Q4 2026 results in early May that exceeded analyst expectations, with revenue reaching $346 million — up 5% reported and 9% organically excluding CSL — while adjusted EPS of $1.29 beat the Zacks Consensus Estimate. Full-year adjusted EPS came in at $4.96, up 9% year-over-year, and free cash flow improved by $65 million to $210 million.
Plasma segment momentum was a standout, with organic growth excluding CSL reaching 13% in the quarter and 20% for the full year, surpassing the company's revised guidance range of 17% to 19%. CEO Christopher Simon noted that fiscal 2026 represented a record year for Plasma, supported by share gains, pricing, and a return to double-digit collection volume growth in the latter half of the year. Blood Management Technologies also delivered a record quarter with 21% revenue growth, driven by sustained TEG 6s demand and increasing HN cartridge utilization in Europe.
On the analyst front, BofA Securities upgraded Haemonetics from Neutral to Buy on May 22, citing improving fundamentals. In July, Mizuho maintained its Outperform rating and raised its price target to $90, while Citi raised its target to $79. The company also gained visibility through inclusion in multiple Russell value and small-cap indexes, a technical catalyst that can generate incremental demand from index-tracking funds. Additionally, Haemonetics announced a segment restructuring effective fiscal Q1 2027, consolidating from three to two reportable segments to better align external reporting with how the business is managed.
The innovation pipeline has also advanced meaningfully. The FDA cleared Persona PLUS, a next-generation plasma collection technology that improves plasma yield by a mid-single-digit percentage, and the PerQseal Elite large-bore vascular closure device — acquired through the Vivasure Medical transaction — is currently under FDA review, representing a potential catalyst for the Interventional Technologies franchise.
Trending AI Robots
For investors seeking data-driven approaches to navigate stocks like Haemonetics, Tickeron provides a dedicated Trending AI Robots page showcasing a curated selection of top-performing AI trading bots. While Tickeron offers hundreds of AI-powered trading bots covering thousands of tickers across various markets, only the most relevant and consistently high-performing strategies appear in this section. These bots vary by trading style, holding period, and risk profile — from short-term momentum strategies to longer-term trend-following approaches — enabling users to identify automated trading solutions aligned with their investment preferences. The platform provides transparency into performance metrics, allowing investors to evaluate bot track records before making decisions. Exploring the Trending AI Robots section can offer valuable insight into how AI-driven strategies are currently positioning across the market.
2026 Outlook and What Investors Should Watch
Haemonetics enters fiscal 2027 with a clear set of priorities and visible growth drivers. Management has guided for 4% to 7% reported revenue growth, with mid-single-digit expansion expected in both Plasma and MedSurg segments. Adjusted operating margins are projected to expand 50 to 100 basis points, and adjusted EPS is expected to grow broadly in line with revenue. Key catalysts to watch include the Persona PLUS commercial rollout — which management described as generating strong customer enthusiasm with multiple adoptions already underway — and the FDA decision on PerQseal Elite, which could open access to the estimated $300 million large-bore vascular closure market.
On the risk side, investors should monitor Interventional Technologies execution as the company works to reinvigorate vascular closure growth after a fiscal 2026 in which the segment declined 9%. While management has expressed renewed confidence, citing lapped headwinds from OEM softness and pulsed-field ablation impacts, sustained improvement will be essential. Tariff exposure, a leveraged balance sheet with $1.2 billion in total debt, and potential collection volume variability in plasma markets represent additional factors worth tracking. The company's next quarterly earnings report — expected in early August 2026 — should provide the first look at fiscal 2027 performance against the new segment structure.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
HAE's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for HAE turned positive on July 28, 2026. Looking at past instances where HAE's MACD turned positive, the stock continued to rise in of 42 cases over the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on July 15, 2026. You may want to consider a long position or call options on HAE as a result. In of 71 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The 50-day moving average for HAE moved above the 200-day moving average on June 24, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where HAE advanced for three days, in of 345 cases, the price rose further within the following month. The odds of a continued upward trend are .
Bearish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 10 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where HAE declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
HAE broke above its upper Bollinger Band on July 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for HAE entered a downward trend on July 20, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. HAE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. HAE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock better than average.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.883) is normal, around the industry mean (10.948). P/E Ratio (41.727) is within average values for comparable stocks, (63.950). Projected Growth (PEG Ratio) (1.366) is also within normal values, averaging (4.043). HAE has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.016). P/S Ratio (3.037) is also within normal values, averaging (35.779).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of blood processing systems
Industry MedicalNursingServices